GliomaASL-TDDNCT07687277
3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma Surgery
An observational study of Glioma and Brain Neoplasms, run by Lanzhou University Second Hospital at 1 site in China.
Trial summary
Background: Differentiating true progression (TP) from pseudoprogression (PsP) after glioma surgery remains a major clinical challenge because conventional magnetic resonance imaging (MRI) often cannot reliably distinguish these conditions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glioma, Brain Neoplasms
- What is being tested?
- Multiparametric MRI (3D-ASL and TDD-MRI)
- How many people
- 75 participants
- Where
- 1 siteChina
- Study dates
- 1 Mar 2024to 30 Jul 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with histopathologically confirmed glioma who develop suspected tumor progression during postoperative follow-up at Lanzhou University Second Hospital and undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI).
Who may be able to join
- Age 18 years or older.
- Histopathologically confirmed glioma.
- Received standard postoperative treatment or routine clinical treatment.
- New or enlarged contrast-enhancing lesion on follow-up MRI suggestive of tumor progression.
- Able to undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI).
- MRI image quality sufficient for image processing, registration, lesion segmentation, and quantitative parameter extraction.
- Written informed consent provided by the participant or legally authorized representative.
Who cannot join
- Incomplete clinical, pathological, or imaging follow-up data.
- MRI images with severe motion artifacts, susceptibility artifacts, or geometric distortion affecting image analysis.
- Failure to complete routine MRI, 3D-ASL, or TDD-MRI examinations according to the study protocol.
- Lesions too small or poorly defined for reliable three-dimensional volume-of-interest delineation and parameter extraction.
- Any other condition judged by the investigators to make participation inappropriate.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Value of Multiparametric Imaging Based on Three-Dimensional Arterial Spin Labeling Combined With Time-Dependent Diffusion MRI in Differentiating True Progression From Pseudoprogression After Glioma Surgery
Background: Differentiating true progression (TP) from pseudoprogression (PsP) after glioma surgery remains a major clinical challenge because conventional magnetic resonance imaging (MRI) often cannot reliably distinguish these conditions.
Objective: This prospective observational diagnostic accuracy study aims to evaluate the value of multiparametric imaging based on three-dimensional arterial spin labeling (3D-ASL) combined with time-dependent diffusion MRI (TDD-MRI) for differentiating TP from PsP in postoperative glioma patients.
Read more
Methods: Consecutive adult patients with suspected tumor progression after glioma surgery will undergo routine MRI, 3D-ASL, and TDD-MRI examinations. Quantitative perfusion and diffusion parameters will be extracted, and a combined imaging model will be developed and evaluated. Final diagnosis will be established according to pathological findings when available or by longitudinal clinical and imaging follow-up based on the Response Assessment in Neuro-Oncology (RANO) criteria.
Expected Outcomes: The primary outcome is the diagnostic performance of the combined imaging model, assessed by the area under the receiver operating characteristic curve (AUC). The study is expected to provide a noninvasive imaging strategy for distinguishing TP from PsP and to support clinical decision-making during postoperative follow-up.
Read the detailed description
Glioma is the most common primary malignant tumor of the central nervous system and is characterized by high invasiveness and a high recurrence rate. During postoperative follow-up after surgery and adjuvant therapy, newly developed or enlarged contrast-enhancing lesions may represent either true progression (TP) or treatment-related pseudoprogression (PsP). Because these entities require substantially different clinical management, accurate differentiation is essential.
Histopathological confirmation remains the reference standard but is invasive and not feasible for all patients. Conventional MRI has limited diagnostic accuracy because TP and PsP often demonstrate overlapping imaging characteristics. Advanced functional MRI techniques have therefore attracted increasing interest for improving noninvasive diagnosis.
Three-dimensional arterial spin labeling (3D-ASL) provides quantitative assessment of cerebral perfusion without exogenous contrast agents, whereas time-dependent diffusion MRI (TDD-MRI) characterizes tissue microstructure by measuring water diffusion under different diffusion times. These techniques provide complementary information regarding tumor vascularity and cellular architecture.
This is a single-center, prospective observational diagnostic accuracy study conducted at Lanzhou University Second Hospital. Approximately 75 consecutive postoperative glioma patients with suspected disease progression will be enrolled. All participants will undergo routine MRI, 3D-ASL, and TDD-MRI examinations according to a standardized imaging protocol. Quantitative imaging parameters, including relative cerebral blood flow (rCBF), ADC20Hz, ADC40Hz, Cellularity, and Diameter, will be extracted after image preprocessing and lesion segmentation.
Participants will not receive any additional therapeutic intervention as part of the study. Clinical management will be determined by treating physicians according to routine clinical practice. Final classification of TP or PsP will be established using pathological confirmation whenever available or comprehensive longitudinal clinical and imaging follow-up according to the RANO 2.0 criteria.
The primary objective is to evaluate the diagnostic performance of the combined 3D-ASL and TDD-MRI model using the area under the receiver operating characteristic curve (AUC). Secondary objectives include evaluating the diagnostic performance of individual imaging parameters, comparing diagnostic models, assessing calibration and clinical utility, determining interobserver agreement, and exploring the influence of clinicopathological factors on model performance.
The findings of this study are expected to establish a reliable, noninvasive multiparametric MRI strategy for differentiating TP from PsP after glioma surgery, thereby facilitating individualized postoperative management and reducing unnecessary invasive procedures.
- Conditions
- Glioma, Brain Neoplasms
- Being tested
- Multiparametric MRI (3D-ASL and TDD-MRI)
- Keywords
- Three-Dimensional Arterial Spin Labeling, 3D-ASL, Time-Dependent Diffusion MRI, TDD-MRI, True Progression, Pseudoprogression, Magnetic Resonance Imaging, Diagnostic Accuracy, Multiparametric MRI, Glioma Surgery, RANO, Cerebral Blood Flow, Diffusion MRI
- Medical subject headings
- Glioma, Brain Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multiparametric MRI (3D-ASL and TDD-MRI)Diagnostic test
Participants undergo standardized multiparametric magnetic resonance imaging, including routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI). Quantitative perfusion and diffusion parameters are extracted for evaluation of their diagnostic performance in differentiating true progression from pseudoprogression after glioma surgery. No experimental therapeutic intervention is administered as part of the study.
| Study group | Role | What they receive |
|---|---|---|
| True Progression (TP) | Participants with suspected postoperative glioma progression who are ultimately diagnosed with true progression based on histopathological findings when available or comprehensive longitudinal clinical and imaging follow-up according to the RANO 2.0 criteria. All participants undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI). Receives: Diagnostic Test: Multiparametric MRI (3D-ASL and TDD-MRI) | |
| Pseudoprogression (PsP) | Participants with suspected postoperative glioma progression who are ultimately diagnosed with pseudoprogression based on histopathological findings when available or comprehensive longitudinal clinical and imaging follow-up according to the RANO 2.0 criteria. All participants undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI). Receives: Diagnostic Test: Multiparametric MRI (3D-ASL and TDD-MRI) |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUC of the Combined 3D-ASL and TDD-MRI Model
Area under the receiver operating characteristic curve (AUC) of the combined three-dimensional arterial spin labeling (3D-ASL) and time-dependent diffusion MRI (TDD-MRI) model for differentiating true progression from pseudoprogression after glioma surgery.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Secondary outcomes (15)
AUC of rCBFmean
Area under the receiver operating characteristic curve (AUC) of mean relative cerebral blood flow (rCBFmean) for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of rCBFmax
Area under the receiver operating characteristic curve (AUC) of maximum relative cerebral blood flow (rCBFmax) for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of rCBFmin
Area under the receiver operating characteristic curve (AUC) of minimum relative cerebral blood flow (rCBFmin) for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of ADC20Hz
Area under the receiver operating characteristic curve (AUC) of ADC20Hz derived from time-dependent diffusion MRI for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of ADC40Hz
Area under the receiver operating characteristic curve (AUC) of ADC40Hz derived from time-dependent diffusion MRI for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of Cellularity
Area under the receiver operating characteristic curve (AUC) of the Cellularity parameter derived from time-dependent diffusion MRI for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of Diameter
Area under the receiver operating characteristic curve (AUC) of the Diameter parameter derived from time-dependent diffusion MRI for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Sensitivity of the Combined 3D-ASL and TDD-MRI Model
Sensitivity of the combined 3D-ASL and TDD-MRI model for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Specificity of the Combined 3D-ASL and TDD-MRI Model
Specificity of the combined 3D-ASL and TDD-MRI model for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Youden Index of the Combined 3D-ASL and TDD-MRI Model
Youden index of the combined 3D-ASL and TDD-MRI model for differentiating true progression from pseudoprogression.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Optimal Cutoff of the Combined 3D-ASL and TDD-MRI Model
Optimal cutoff value of the combined 3D-ASL and TDD-MRI model determined from receiver operating characteristic curve analysis.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC Difference Between the Combined Model and the Best Individual MRI Parameter
Difference in AUC between the combined 3D-ASL and TDD-MRI model and the best-performing individual MRI parameter.
Measured: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Hosmer-Lemeshow Goodness-of-Fit P Value
Hosmer-Lemeshow goodness-of-fit test P value for evaluating calibration of the combined 3D-ASL and TDD-MRI model.
Measured: After completion of model construction and statistical analysis
Clinical Net Benefit of the Combined 3D-ASL and TDD-MRI Model
Clinical net benefit of the combined 3D-ASL and TDD-MRI model assessed using decision curve analysis.
Measured: After completion of model construction and statistical analysis
Interobserver Agreement for MRI Parameter Measurements
Interobserver agreement for quantitative MRI parameter measurements assessed using the intraclass correlation coefficient (ICC).
Measured: At image analysis after completion of MRI examinations
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2026
- Study start1 Mar 2024
- Primary completion28 Feb 2026
- Study completion30 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GliomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 75 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lanzhou University Second Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Junwei Chang, Lanzhou University Second Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07687277
- Sponsor's protocol ID
- LZU2H-MRI-2024A1221
- Acronym
- ASL-TDD
- Status last verified
- Jul 2026
- First submitted
- 29 Jun 2026
- Last updated
- 7 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because the study data contain potentially identifiable clinical and imaging information. De-identified aggregate results may be reported in publications.
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Value of Multiparametric Imaging Based on Three-Dimensional Arterial Spin Labeling Combined With Time-Dependent Diffusion MRI in Differentiating True Progression From Pseudoprogression After Glioma Surgery
- ClinicalTrials.gov ID
- NCT07687277
- Acronym / sponsor ID
- ASL-TDD / LZU2H-MRI-2024A1221
- Conditions
- Glioma, Brain Neoplasms
- Keywords
- Three-Dimensional Arterial Spin Labeling, 3D-ASL, Time-Dependent Diffusion MRI, TDD-MRI, True Progression, Pseudoprogression, Magnetic Resonance Imaging, Diagnostic Accuracy
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 75 participants (actual)
- Lead sponsor
- Lanzhou University Second HospitalUniversity, hospital or other
- Study start
- 1 Mar 2024 (actual)
- Primary completion
- 28 Feb 2026 (actual)
- Study completion
- 30 Jul 2026 (estimated)
- First posted
- 7 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background: Differentiating true progression (TP) from pseudoprogression (PsP) after glioma surgery remains a major clinical challenge because conventional magnetic resonance imaging (MRI) often cannot reliably distinguish these conditions.
Objective: This prospective observational diagnostic accuracy study aims to evaluate the value of multiparametric imaging based on three-dimensional arterial spin labeling (3D-ASL) combined with time-dependent diffusion MRI (TDD-MRI) for differentiating TP from PsP in postoperative glioma patients.
Methods: Consecutive adult patients with suspected tumor progression after glioma surgery will undergo routine MRI, 3D-ASL, and TDD-MRI examinations. Quantitative perfusion and diffusion parameters will be extracted, and a combined imaging model will be developed and evaluated. Final diagnosis will be established according to pathological findings when available or by longitudinal clinical and imaging follow-up based on the Response Assessment in Neuro-Oncology (RANO) criteria.
Expected Outcomes: The primary outcome is the diagnostic performance of the combined imaging model, assessed by the area under the receiver operating characteristic curve (AUC). The study is expected to provide a noninvasive imaging strategy for distinguishing TP from PsP and to support clinical decision-making during postoperative follow-up.
Detailed description
Glioma is the most common primary malignant tumor of the central nervous system and is characterized by high invasiveness and a high recurrence rate. During postoperative follow-up after surgery and adjuvant therapy, newly developed or enlarged contrast-enhancing lesions may represent either true progression (TP) or treatment-related pseudoprogression (PsP). Because these entities require substantially different clinical management, accurate differentiation is essential.
Histopathological confirmation remains the reference standard but is invasive and not feasible for all patients. Conventional MRI has limited diagnostic accuracy because TP and PsP often demonstrate overlapping imaging characteristics. Advanced functional MRI techniques have therefore attracted increasing interest for improving noninvasive diagnosis.
Three-dimensional arterial spin labeling (3D-ASL) provides quantitative assessment of cerebral perfusion without exogenous contrast agents, whereas time-dependent diffusion MRI (TDD-MRI) characterizes tissue microstructure by measuring water diffusion under different diffusion times. These techniques provide complementary information regarding tumor vascularity and cellular architecture.
This is a single-center, prospective observational diagnostic accuracy study conducted at Lanzhou University Second Hospital. Approximately 75 consecutive postoperative glioma patients with suspected disease progression will be enrolled. All participants will undergo routine MRI, 3D-ASL, and TDD-MRI examinations according to a standardized imaging protocol. Quantitative imaging parameters, including relative cerebral blood flow (rCBF), ADC20Hz, ADC40Hz, Cellularity, and Diameter, will be extracted after image preprocessing and lesion segmentation.
Participants will not receive any additional therapeutic intervention as part of the study. Clinical management will be determined by treating physicians according to routine clinical practice. Final classification of TP or PsP will be established using pathological confirmation whenever available or comprehensive longitudinal clinical and imaging follow-up according to the RANO 2.0 criteria.
The primary objective is to evaluate the diagnostic performance of the combined 3D-ASL and TDD-MRI model using the area under the receiver operating characteristic curve (AUC). Secondary objectives include evaluating the diagnostic performance of individual imaging parameters, comparing diagnostic models, assessing calibration and clinical utility, determining interobserver agreement, and exploring the influence of clinicopathological factors on model performance.
The findings of this study are expected to establish a reliable, noninvasive multiparametric MRI strategy for differentiating TP from PsP after glioma surgery, thereby facilitating individualized postoperative management and reducing unnecessary invasive procedures.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| True Progression (TP) | – | Diagnostic Test: Multiparametric MRI (3D-ASL and TDD-MRI)Participants with suspected postoperative glioma progression who are ultimately diagnosed with true progression based on histopathological findings when available or comprehensive longitudinal clinical and imaging follow-up according to the RANO 2.0 criteria. All participants undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI). |
| Pseudoprogression (PsP) | – | Diagnostic Test: Multiparametric MRI (3D-ASL and TDD-MRI)Participants with suspected postoperative glioma progression who are ultimately diagnosed with pseudoprogression based on histopathological findings when available or comprehensive longitudinal clinical and imaging follow-up according to the RANO 2.0 criteria. All participants undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with histopathologically confirmed glioma who develop suspected tumor progression during postoperative follow-up at Lanzhou University Second Hospital and undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI).
Key inclusion criteria (7 listed)
- Age 18 years or older.
- Histopathologically confirmed glioma.
- Received standard postoperative treatment or routine clinical treatment.
- New or enlarged contrast-enhancing lesion on follow-up MRI suggestive of tumor progression.
- Able to undergo routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI).
Key exclusion criteria (5 listed)
- Incomplete clinical, pathological, or imaging follow-up data.
- MRI images with severe motion artifacts, susceptibility artifacts, or geometric distortion affecting image analysis.
- Failure to complete routine MRI, 3D-ASL, or TDD-MRI examinations according to the study protocol.
- Lesions too small or poorly defined for reliable three-dimensional volume-of-interest delineation and parameter extraction.
- Any other condition judged by the investigators to make participation inappropriate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multiparametric MRI (3D-ASL and TDD-MRI)Participants undergo standardized multiparametric magnetic resonance imaging, including routine MRI, three-dimensional arterial spin labeling (3D-ASL), and time-dependent diffusion MRI (TDD-MRI). Quantitative perfusion and diffusion parameters are extracted for evaluation of their diagnostic performance in differentiating true progression from pseudoprogression after glioma surgery. No experimental therapeutic intervention is administered as part of the study. | Diagnostic test | Pseudoprogression (PsP), True Progression (TP) |
Primary outcome
AUC of the Combined 3D-ASL and TDD-MRI Model
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Area under the receiver operating characteristic curve (AUC) of the combined three-dimensional arterial spin labeling (3D-ASL) and time-dependent diffusion MRI (TDD-MRI) model for differentiating true progression from pseudoprogression after glioma surgery.
15 secondary outcomes
AUC of rCBFmean
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of rCBFmax
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of rCBFmin
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of ADC20Hz
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of ADC40Hz
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of Cellularity
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC of Diameter
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Sensitivity of the Combined 3D-ASL and TDD-MRI Model
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Specificity of the Combined 3D-ASL and TDD-MRI Model
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Youden Index of the Combined 3D-ASL and TDD-MRI Model
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Optimal Cutoff of the Combined 3D-ASL and TDD-MRI Model
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
AUC Difference Between the Combined Model and the Best Individual MRI Parameter
Time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)
Hosmer-Lemeshow Goodness-of-Fit P Value
Time frame: After completion of model construction and statistical analysis
Clinical Net Benefit of the Combined 3D-ASL and TDD-MRI Model
Time frame: After completion of model construction and statistical analysis
Interobserver Agreement for MRI Parameter Measurements
Time frame: At image analysis after completion of MRI examinations
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because the study data contain potentially identifiable clinical and imaging information. De-identified aggregate results may be reported in publications.
Related trials for Glioma
RecruitingPhase 2/3
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma
Active, not recruitingPhase 1/2
RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors
Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma
RecruitingPhase 1
Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Not yet recruiting
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
RecruitingEarly Phase 1
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
CNS Embryonal Tumor, CNS, Medulloblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glioma and Brain Neoplasms, run by Lanzhou University Second Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUC of the Combined 3D-ASL and TDD-MRI Model (time frame: From enrollment through completion of clinical and imaging follow-up (up to 12 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2026.